YUTIQ^® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Discover Continuous
Calm In Uveitis

This site is intended for US healthcare professionals only.

Press Release Important Safety Information Full Prescribing Information

Address:

480 Pleasant Street
Suite B300
Watertown, MA 02472
1-833-EyePoint (1-833-393-7646)

Press Release
Important Safety Information
Full Prescribing Information

Address:
480 Pleasant Street
Suite B300
Watertown, MA 02472
1-833-EyePoint (1-833-393-7646)

This site is intended for US healthcare professionals only.

Patient Experience with YUTIQ

Listen to three patients tell their stories about chronic noninfectious posterior uveitis and their treatment with YUTIQ. Your experience may differ.

Christine

Dr. Dayani’s Perspective

David

Dr. Dayani’s Perspective

Vickie

Download the patient brochure

If you have questions about YUTIQ, download the brochure to learn more.

See the patient website

INDICATIONS AND USAGE

YUTIQ^® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

IMPORTANT SAFETY INFORMATION

Contraindications

Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

Hypersensitivity: YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.

Warnings and Precautions

Intravitreal Injection-related Effects: Intravitreal injections, including those with YUTIQ, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.

Steroid-related Effects: Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

Adverse Reactions

In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

Please see full Prescribing Information.

References: 1. YUTIQ^® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. EyePoint Pharmaceuticals, Inc. October 2018. 2. Data on file.

This site is intended for US healthcare professionals only.

YUTIQ, the YUTIQ logo, and the EyePoint logo are registered trademarks and EyePoint Assist is a service mark of EyePoint Pharmaceuticals, Inc.

03/2021

US-YUT-2100024

03/2021 US-YUT-2100024

Discover ContinuousCalm In Uveitis

Address:

Patient Experience with YUTIQ

Christine

David

Vickie

Download the patient brochure

See the patient website

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

Contraindications

Warnings and Precautions

Adverse Reactions

IMPORTANT SAFETY INFORMATION

Contraindications

IMPORTANT SAFETY INFORMATION

Contraindications

Patient Treatment Journey Tool

Discover Continuous
Calm In Uveitis